Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 118 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Anticonvulsant Agent Clear all
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 5, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

Panitumumab and Irinotecan for Malignant Gliomas

NCT01017653
View directory record Official record
Conditions
Malignant Glioma of Brain
Interventions
Irinotecan, Panitumumab
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Sep 5, 2026, 8:30 AM EDT
Terminated Phase 4 Interventional Results available

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

NCT03891264
View directory record Official record
Conditions
Back Pain, Low
Interventions
Cannabidiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

NCT02120365
View directory record Official record
Conditions
Alcoholism
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

R33: Levetiracetam in Early Psychosis

NCT04317807
View directory record Official record
Conditions
Early Psychosis
Interventions
Levetiracetam Pill, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 5, 2026, 8:30 AM EDT
Completed No phase listed Observational

Factors Associated With in Suboptimal Prescribing for Older Patients With Epilepsy

NCT00144001
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
66 Years and older
Enrollment
9,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
2
States / cities
Bedford, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 5, 2026, 8:30 AM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Results available

BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients

NCT02404168
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine (brand Lamictal), lamotrigine (generic Teva)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 76 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 5, 2026, 8:30 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 5, 2026, 8:30 AM EDT
Terminated Phase 4 Interventional Results available

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346
View directory record Official record
Conditions
Epilepsy
Interventions
ezogabine/retigabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Bethesda, Maryland • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers

NCT00006395
View directory record Official record
Conditions
Healthy
Interventions
St. John's Wort
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 8:30 AM EDT
Withdrawn No phase listed Observational

Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy

NCT04308252
View directory record Official record
Conditions
Epilepsy in Children, Pharmaco-Resistant Epilepsy
Interventions
Not listed
Lead sponsor
Senda Biosciences
Industry
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

NCT00288366
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 5, 2026, 8:30 AM EDT
Completed No phase listed Observational

Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy

NCT01296880
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
17 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 5, 2026, 8:30 AM EDT
Completed No phase listed Observational

A Study to Look at Antiepileptic Drug Levels While on Lamictal or Depakote With or Without an Oral Contraceptive

NCT00296413
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

NCT01137890
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Zonisamide, Placebo, Cocaine Hydrochloride, Neurocognitive and Performance Battery, Smoking Assessments
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT02535091
View directory record Official record
Conditions
Partial Epilepsy
Interventions
YKP3089
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ginkgo Biloba on Phenytoin Elimination

NCT00011063
View directory record Official record
Conditions
Healthy
Interventions
Ginkgo Biloba
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 8:30 AM EDT
Withdrawn Phase 2 Interventional

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

NCT01167335
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Mobile, Alabama • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

NCT00809146
View directory record Official record
Conditions
Status Epilepticus
Interventions
Intramuscular route of active treatment, Intravenous route of active treatment
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
Not listed
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Levetiracetam in the Management of Bipolar Depression

NCT00566150
View directory record Official record
Conditions
Bipolar Depression
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 5, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

NCT00068770
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
radiation therapy, Celecoxib
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 3 Interventional

Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)

NCT00108576
View directory record Official record
Conditions
PTSD
Interventions
Divalproex, placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 5, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

NCT00354913
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
hydroxyurea, imatinib mesylate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 5, 2026, 8:30 AM EDT